Suchergebnisse - "Jae Hui Kim"

PubPharm (7)

1

Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization

in: Scientific Reports | 2022

von Jae Hui Kim | Jong Woo Kim | Chul Gu Kim

2

Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

in: Journal of Clinical Medicine | 2021

von Jae-Hui Kim | Jong-Woo Kim | Chul-Gu Kim

3

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy

in: Journal of Clinical Medicine | 2021

von Young-Joon Jeon | Jae-Hui Kim | Jong-Woo Kim | +1

4

Eyes that Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion

in: Journal of Ophthalmology | 2021

von Jae Hui Kim | Jong Woo Kim | Chul Gu Kim

5

Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis

in: BMJ Open | 2020

von Hyesung Lee | Dongwon Yoon | Yeonkyung Lee | +2

6

Long-Term Outcomes of Switching from Fixed-Dose to As-Needed Regimen for Treating Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy

in: Journal of Clinical Medicine | 2020

von Jae Hui Kim | Jong Woo Kim | Chul Gu Kim | +1

7

Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring

in: Journal of Clinical Medicine | 2020

von Jae Hui Kim | Jong Woo Kim | Chul Gu Kim | +1

1
[1]